Fresh Tracks Therapeutics, Inc.

DB:VCC Stock Report

Market Cap: €5.0m

Fresh Tracks Therapeutics Valuation

Is VCC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VCC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VCC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VCC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VCC?

Key metric: As VCC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VCC. This is calculated by dividing VCC's market cap by their current revenue.
What is VCC's PS Ratio?
PS Ratio0.7x
SalesUS$8.01m
Market CapUS$5.38m

Price to Sales Ratio vs Peers

How does VCC's PS Ratio compare to its peers?

The above table shows the PS ratio for VCC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.9x
CNW co.don
0.7xn/a€6.5m
2INV 2invest
8.2xn/a€63.2m
MDG1 Medigene
2.8x13.3%€20.6m
SBH Sangui Biotech International
3.8xn/a€419.8k
VCC Fresh Tracks Therapeutics
0.7xn/a€5.4m

Price-To-Sales vs Peers: VCC is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (7.9x).

Price to Sales Ratio vs Industry

How does VCC's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.7.9x21.8%
VCC Fresh Tracks Therapeutics
 0.7xn/aUS$5.38m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
VCC 0.7xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.7.9x42.4%
VCC Fresh Tracks Therapeutics
 0.7xn/aUS$5.38m
No more companies

Price-To-Sales vs Industry: VCC is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Biotechs industry average (10.8x).

Price to Sales Ratio vs Fair Ratio

What is VCC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VCC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VCC's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.55

7D

2.0%

1Y

95.6%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.20

7D

5.0%

1Y

23.7%

Pharming Group

€478.2m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

1.8%

1Y

-31.2%